What are the main financial results announced by BMY in this filing?

This 8-K primarily serves to furnish the press release announcing Bristol-Myers Squibb's financial results for the fourth quarter and full year of 2018. While the 8-K itself doesn't detail these results, it directs investors to Exhibit 99.1 (the earnings press release) and Exhibit 99.2 (supplemental information) for the specific figures.

What is the most significant event discussed in this filing beyond the quarterly results?

The most significant event highlighted is the proposed acquisition of Celgene Corporation. The filing details the ongoing process, including regulatory disclosures, information for proxy solicitations, and a strong emphasis on the associated risks and forward-looking statements.

Where can I find more information about the proposed Celgene acquisition?

Investors are strongly encouraged to read the joint proxy statement/prospectus and other relevant documents that Bristol-Myers Squibb and Celgene will file with the SEC. These documents will contain crucial information about the transaction, its risks, and potential benefits. Free copies will be available on the SEC's website and the respective companies' investor relations pages.

Does this filing contain audited financial statements?

No, this 8-K filing does not contain audited financial statements directly. It furnishes an earnings press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) which contain the financial results. For audited financial statements, investors should refer to BMY's Annual Report on Form 10-K and subsequent filings.

BMY 8-K: Earnings & Results & Regulation FD

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K on January 24, 2019, primarily to furnish its fourth quarter and full-year 2018 earnings press release and related supplemental information. This filing provides investors with key financial results for the preceding year and quarter. Additionally, the company provided a presentation detailing financial and operating initiatives, which was made available during their earnings call. Crucially, this report also serves to inform investors about the ongoing proposed acquisition of Celgene Corporation. It details the regulatory filings, participant disclosures, and forward-looking statements related to this significant transaction. Investors are urged to review the forthcoming joint proxy statement/prospectus and other SEC filings for comprehensive information on the Celgene acquisition, which will contain important details regarding risks, potential synergies, and the integration process.

Key Highlights

1BMY announced its financial results for the fourth quarter and full year of 2018 via an earnings press release (Exhibit 99.1).
2Supplemental financial information and presentation materials (Exhibits 99.2 and 99.3) were also provided on the company's website.
3The report includes extensive disclosures and cautionary statements regarding the proposed acquisition of Celgene Corporation.
4Investors are directed to review future filings, including a joint proxy statement/prospectus, for detailed information on the Celgene transaction.
5The company provided information on potential participants in the solicitation of proxies related to the Celgene acquisition.
6Significant emphasis is placed on forward-looking statements concerning the risks and uncertainties associated with the Celgene acquisition and its potential benefits.

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Jan 24, 2019)

Summary

Key Highlights

Frequently Asked Questions